They can be detected in approximately 6% of patients with newly diagnosed AML and 20% of AML patients with t(8;21) RUNX1-RUNXT1 and 30% of AML patients with inv(16) or t(16;16) CBFB-MYH11 (the core binding factor AMLs-CBF-AML). This evidence concerns the gene CEBPZ and acute myeloid leukemia.